57 related articles for article (PubMed ID: 38572480)
21. Self-efficacy in symptom management for adolescents and young adults with cancer: a systematic review.
Thornton CP; Li M; Yeh CH; Ruble K
Support Care Cancer; 2021 Jun; 29(6):2851-2862. PubMed ID: 33403400
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-7a2 Regulates Prolactin in Developing Lactotrophs and Prolactinoma Cells.
LaPierre MP; Godbersen S; Torres Esteban M; Schad AN; Treier M; Ghoshdastider U; Stoffel M
Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33248443
[TBL] [Abstract][Full Text] [Related]
23. The importance of specialized sleep investigations in children with a suprasellar tumor.
van Schaik J; Pillen S; van Litsenburg RRL; Vandenbussche NLE; de Bont JM; Schouten-van Meeteren AYN; van Santen HM
Pituitary; 2020 Dec; 23(6):613-621. PubMed ID: 32691357
[TBL] [Abstract][Full Text] [Related]
24. Self-efficacy and health-related quality of life in chronic obstructive pulmonary disease: A meta-analysis.
Selzler AM; Habash R; Robson L; Lenton E; Goldstein R; Brooks D
Patient Educ Couns; 2020 Apr; 103(4):682-692. PubMed ID: 31859120
[TBL] [Abstract][Full Text] [Related]
25. Surgery for prolactinomas: a better choice?
Honegger J; Nasi-Kordhishti I; Aboutaha N; Giese S
Pituitary; 2020 Feb; 23(1):45-51. PubMed ID: 31853793
[TBL] [Abstract][Full Text] [Related]
26. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new.
Chanson P; Maiter D
Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373
[TBL] [Abstract][Full Text] [Related]
27. Body self-image disturbances in women with prolactinoma.
Pereira HS; Naliato EC; Moraes AB; Gadelha MR; Vieira Neto L; Almeida RM; Nardi AE; Violante AH
Braz J Psychiatry; 2020; 42(1):33-39. PubMed ID: 31314867
[TBL] [Abstract][Full Text] [Related]
28. Interventions to enhance self-efficacy in cancer patients: A meta-analysis of randomized controlled trials.
Merluzzi TV; Pustejovsky JE; Philip EJ; Sohl SJ; Berendsen M; Salsman JM
Psychooncology; 2019 Sep; 28(9):1781-1790. PubMed ID: 31206917
[TBL] [Abstract][Full Text] [Related]
29. Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size.
Burke WT; Penn DL; Castlen JP; Donoho DA; Repetti CS; Iuliano S; Barkhoudarian G; Laws ER
J Neurosurg; 2019 Jun; 133(2):321-328. PubMed ID: 31200381
[TBL] [Abstract][Full Text] [Related]
30. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
[TBL] [Abstract][Full Text] [Related]
31. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
Zhang SL; Tang HB; Hu JT; Zang ZL; Ding X; Li S; Yang H
Biomed Pharmacother; 2019 Mar; 111():638-648. PubMed ID: 30611988
[TBL] [Abstract][Full Text] [Related]
32. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
Ioachimescu AG; Fleseriu M; Hoffman AR; Vaughan Iii TB; Katznelson L
Eur J Endocrinol; 2019 Jan; 180(1):31-40. PubMed ID: 30400048
[TBL] [Abstract][Full Text] [Related]
33. Prolactin function and putative expression in the brain.
Cabrera-Reyes EA; Limón-Morales O; Rivero-Segura NA; Camacho-Arroyo I; Cerbón M
Endocrine; 2017 Aug; 57(2):199-213. PubMed ID: 28634745
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of curative effect of surgical therapy for male prolactinoma].
Chen MT; Song YJ; Lian W; Xing B; Yao Y; Feng M; Wang RZ
Zhonghua Yi Xue Za Zhi; 2016 May; 96(19):1477-80. PubMed ID: 27266490
[TBL] [Abstract][Full Text] [Related]
35. Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence.
Landeiro JA; Fonseca EO; Monnerat AL; Taboada GF; Cabral GA; Antunes F
Surg Neurol Int; 2015; 6():179. PubMed ID: 26674325
[TBL] [Abstract][Full Text] [Related]
36. Psychological aspects of endocrine disease.
Sonino N; Guidi J; Fava GA
J R Coll Physicians Edinb; 2015 Mar; 45(1):55-9. PubMed ID: 25874833
[TBL] [Abstract][Full Text] [Related]
37. Prolactinomas.
Glezer A; Bronstein MD
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
[TBL] [Abstract][Full Text] [Related]
38. Prolactin-derived vasoinhibins increase anxiety- and depression-related behaviors.
Zamorano M; Ledesma-Colunga MG; Adán N; Vera-Massieu C; Lemini M; Méndez I; Moreno-Carranza B; Neumann ID; Thebault S; Martínez de la Escalera G; Torner L; Clapp C
Psychoneuroendocrinology; 2014 Jun; 44():123-32. PubMed ID: 24767626
[TBL] [Abstract][Full Text] [Related]
39. Major depressive disorder induced by prolactinoma--a case report.
Liao WT; Bai YM
Gen Hosp Psychiatry; 2014; 36(1):125.e1-2. PubMed ID: 24182617
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists.
Barbosa FR; Silva CM; Lima GA; Warszawski L; Domingues RC; Dominic M; Fontes R; Vieira Neto L; Gadelha MR
Pituitary; 2014 Oct; 17(5):441-9. PubMed ID: 24068456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
